Market Overview

RedHill Earns Long-Awaited Boost On Positive Crohn's Data

RedHill Earns Long-Awaited Boost On Positive Crohn's Data

REDHILL BIOPHAR/S ADR (NASDAQ: RDHL) achieved positive top-line results in its Phase 3 study of RHB-104 in Crohn’s disease, according to a Monday press release.

What Happened

The drug met both primary and secondary endpoints by demonstrating a remission rate superior to that of the placebo and consistent benefit to patients with Crohn’s, according to RedHill. 

RedHill also reported a positive safety profile as well as statistical significance in participants experiencing early remission and sustained remission.

Why It’s Important

RedHill expects the therapy to become a leading Crohn’s treatment. The indication has a market of 1.5 million people who are expected to spend more than $10 billion on therapies in 2018.

“Many patients with Crohn's disease do not achieve remission on current standard-of-care therapies, which are accompanied with poor side effects,” David Graham, the study’s principal investigator, said in the press release. “RHB-104 appears to have the potential to become a promising, new orally administered therapy for this important debilitating disease."

What’s Next

RedHill will present data before the Food and Drug Administration to develop a path to approval and continue to discuss commercialization with potential partners. It expects additional studies will be needed to support a New Drug Application.

The stock was trading up 3.82 percent at $9.79 at the time of publication Monday morning. 

Related Links:

RedHill BioPharma Patiently Awaits Market Recognition As It Achieves Consistent Trial Success

Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4

Posted-In: Crohn's DiseaseBiotech News Top Stories General Best of Benzinga


Related Articles (RDHL)

View Comments and Join the Discussion!

CAT Climbs Into Driver's Seat To Start Earnings Parade, With Fed Meeting Ahead

Mid-Morning Market Update: Markets Down; Caterpillar Tops Q2 Expectations